Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novo Nordisk's YTD Revenues up 23% | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Novo Nordisk’s YTD Revenues up 23%

GLP-1 diabetes sales grow 25% and Obesity care grows by 44%.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novo Nordisk
For the period January 1, 2024 to September 30, 2024.
YTD Revenues: $30.6 billion (+23%)
YTD Earnings: $10.9 billion (+18%)  
Comments: Sales within Diabetes and Obesity care increased by 25% to $28.7 billion, mainly driven by GLP-1 diabetes sales growth of 25% and Obesity care growing by 44%. Rare disease sales increased by 3% to $1.9 billion. Ozempic sales were up 32% to $12.9 billion. Wegovy sales were up 76% to $5.7 billion. Sales in North America increased by 31% and International Operations increased by 13%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters